News

Though approved therapies for multiple sclerosis (MS) exist, the disabling disease remains currently incurable leading to greater interest for promoting healthier lifestyles that could ease or slow disease impacts such as hyperlipidemia, hypertension, diabetes, and heart disease which increase progression of disability, brain injury, and atrophy. In fact,…

Increasing a person’s confidence that they can complete tasks and reach goals in specific situations may benefit patients with relapsing-remitting multiple sclerosis (RRMS). In a new study, researchers used an intensive three-day social cognitive treatment, called Can Do, to increase patients’ self-efficacy, which resulted in long lasting improvements in their health-related…

A large study of multiple sclerosis patients (MS) came to the conclusion that clinical and brain imaging assessments drawn from magnetic resonance imaging (MRI) scans are poor measures of long-term prognosis for patients. The study, “Long-term evolution of multiple sclerosis disability in the treatment era,” published in the journal…

There are no specific therapies that can effectively cure patients with multiple sclerosis. However, there are a number of multiple sclerosis treatment options, particularly for the relapsing-remitting form of the disease. 1.Immunomodulation therapies which can control the inflammation of myelin sheaths and help restore the central nervous system.

As inflammation and neuronal death progressed in the brains of mice with multiple sclerosis (MS), a molecular signaling pathway with a key player called Wnt was seen to come into action in brain areas crucial for memory production, triggering the formation of new neurons. The findings, presented in the study…

Although Tysabri (natalizumab) is a highly effective in treating patients with relapsing-remitting multiple sclerosis (RRMS), some may develop progressive multifocal leukoencephalopathy (PML). According to a new study, this occurs because Tysabri impairs immune surveillance in the central nervous system and reactivates the latent John Cunningham polyomavirus (JCV). The study, “Natalizumab Affects…

The Patient-Centered Outcomes Research Institute (PCORI) recently awarded a sum of $5.5 million to two researchers at the University of California, San Francisco (UCSF). Bardia Nourbakhsh, MD. (Credit: UCSF) Bardia Nourbakhsh, MD, a clinical fellow in Neurology, received a $2 million grant to conduct a randomized, double-blind, placebo-controlled clinical trial to…

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) recently announced that its second annual ACTRIMS Forum will be at the Omni ChampionsGate Feb. 23-25, 2017, in Orlando, Florida. ACTRIMS Forum 2017 promises to be of value to physicians, scientists, researchers, analysts, faculty, and allied health…

Patients with aggressive onset multiple sclerosis, characterized by a rapidly progressing disease course and accumulation of disability, may benefit from early aggressive therapies instead of the escalation approach commonly given multiple sclerosis (MS) patients, according to researchers at Weill-Cornell Medical College. Their article, titled “A study of patients with…

The Multiple Sclerosis (MS) Foundation wants to mark its 30th anniversary by granting 30 more wishes to MS patients in need this year through its Brighter Tomorrow Grant program. To do this, the organization is asking the public to help it raise $30,000 before Dec. 1, so it can increase by 30…

Transcutaneous electrical nerve stimulation (TENS) might be an option to treat spasticity, one of the more common symptoms of multiple sclerosis (MS), according to a literature review conducted by researchers from Universidad de Castilla la Mancha, Toledo and Hospital Nacional de Parapléjicos de Toledo, in Spain.

A review article published in the British Journal of Pharmacology assesses antioxidant approaches for treating neurodegenerative disorders such as multiple sclerosis, Alzheimer’s, Parkinson’s, and amyotrophic lateral sclerosis (ALS). The review, “Microglia antioxidant systems and redox signalling,” notes that certain compounds associated with oxidative stress appear to be promising…

RedHill Biopharma announced that the final patient has completed the last step of its Phase 2 clinical study (CEASE-MS) of RHB-104 as a potential treatment for people with relapsing-remitting multiple sclerosis (RRMS). RHB-104 is an antibiotic oral medication that blocks inflammation in addition to killing bacteria. RHB-104 was originally developed as a treatment for…

Understanding lipid signaling in multiple sclerosis (MS) may be the key to developing more effective therapies for the disease. New work by researchers at Cornell University could bring us closer to unraveling the role of lipids in MS development. Lipids are fat molecules that compose the cellular membranes and surround each organelle inside…

A study analyzing results from three Phase 3 clinical trials shows that Gilenya (fingolimod) effectively prevents relapses in different types of relapsing multiple sclerosis (MS) patients, with the therapy being most efficient in younger patients and those without previous treatment. The findings highlight the importance of starting treatment early, and not…

Do you take your drugs as they are prescribed?  It turns out a lot of us don’t and that is a concern to the people in charge of our healthcare dollars. The California Association of  Health Plans estimates that costs for prescription for chronic diseases such as multiple sclerosis, rheumatoid…

In addition to a new study sponsored by Genentech to test the experimental MS therapy Ocrevus (ocrelizumab) in RMS patients who have had a sub-optimal response to previous disease modifying therapies, the company is also currently recruiting patients with relapsing multiple sclerosis to understand the therapy’s mechanism of action and B-cell biology…

A Phase 3 clinical trial exploring Ocrevus (ocrelizumab) in patients with relapsing-remitting multiple sclerosis (RRMS) is now recruiting participants. The trial, sponsored by Genentech (NCT02637856), is seeking patients who have previously taken a disease-modifying treatment that did not adequately control their disease activity. Participants must be between 18 and 55…

People with multiple sclerosis, especially those with cognitive disabilities, have more problems managing their personal finances — paying bills on time or using a credit card — than those without this disease, researchers report in the study, “Money Management Activities in Persons With Multiple Sclerosis,” published in the…

Multiple sclerosis (MS) patients in the U.S. with higher disability scores also have higher rates of health resource utilization, higher healthcare costs, and lower work productivity and health-related quality of live, according a study by researchers at Adelphi Real World and Abbvie. The study, “Quantifying the…

New research from England indicates that healthcare providers do not communicate enough with their patients about the possible outcomes for their multiple sclerosis (MS). The study, “How Do People with Multiple Sclerosis Experience Prognostic Uncertainty and Prognosis Communication? A Qualitative Study,“ appeared in the journal PLoS One.

My MS Manager has been named by Healthline.com as one of the best multiple sclerosis (MS) apps for the fourth consecutive year. Formerly known as MSAA Self-Care Manager, the free application for Apple iOS and Android smartphones and tablets was created by the Multiple Sclerosis Association of…

The National Multiple Sclerosis Society reported that the Patient-Centered Outcomes Research Institute (PCORI) has granted nearly $20 million in funding to four research projects assessing various multiple sclerosis (MS) therapies for their clinical effectiveness. Two of the grants will cover studies comparing disease-modifying treatments, looking to identify differences…

A new study  focused on an aspect of multiple sclerosis (MS) that is sometimes overlooked by researchers: progressive dwindling, or the tendency over time for people with MS to become increasingly frail and dependent on caregivers, with diminished energy and heightened disability. The report, “Progressive Dwindling in Multiple Sclerosis: An Opportunity…

Researchers at Queen’s University Belfast are studying how myelin might be repaired, in an attempt to reverse the damage caused by multiple sclerosis (MS). The more than £2 million, five-year research grant is jointly funded by  the Wellcome Trust, in its first Investigator Award for Northern Ireland, and by the BBSRC, the Biotechnology and Biosciences…

While the amount of vitamin D supplements, that should be taken by people with MS is not clear, the Scientific Advisory Committee on Nutrition (SACN), Vitamin D working group recently published a report recommending that everyone aged 4 and above should take 10 μg (400 IU) of vitamin D each day.

Gut bacteria and health have been topics of considerable scientific speculation in recent years, and the field of multiple sclerosis (MS) research is no exception. But what do we really know about MS and our intestinal inhabitants? A review, “Emerging Concepts on the Gut Microbiome and Multiple Sclerosis,” published in…

Sanofi Genzyme announced that the Government of Ontario has added Lemtrada (alemtuzumab) to the province’s Exceptional Access Program (EAP), opening coverage to the treatment for eligible patients with relapsing-remitting multiple sclerosis (RRMS). The program facilitates patient access to drugs not funded on the Ontario Drug Benefit (ODB) Formulary, or those…

Building on work began in stroke studies and applying it to multiple sclerosis, researchers in France report that an antibody they developed kept the blood-brain barrier intact in cellular and mice MS models despite the presence of inflammation, preventing immune cells from entering the brain. The key to understanding the study…

Women with multiple sclerosis (MS) and people diagnosed with the disease at a younger age are more likely to have a benign course of MS, remaining fully functional for decades after disease onset, according to researchers at the School of Medicine and Biomedical Sciences in New York. Disease modifying drugs were also found…